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Abstract
Low thyroid hormone (TH) function has been linked to impaired coronary blood flow, reduced density of small arterioles,
and heart failure. Nonetheless, little is known about the mechanisms by which THs regulate coronary microvascular
remodeling. The current study examined the initial cellular events associated with coronary remodeling induced by
triiodothyronine (T3) in hypothyroid rats. Rats with established hypothyroidism, eight weeks after surgical thyroidectomy
(TX), were treated with T3 for 36 or 72 hours. The early effects of T3 treatment on coronary microvasculature were examined
morphometrically. Gene expression changes in the heart were assessed by quantitative PCR Array. Hypothyroidism resulted
in arteriolar atrophy in the left ventricle. T3 treatment rapidly induced small arteriolar muscularization and, within 72 hours,
restored arteriolar density to control levels. Total length of the capillary network was not affected by TX or T3 treatment. T3
treatment resulted in the coordinate regulation of Angiopoietin 1 and 2 expression. The response of Angiopoietins was
consistent with vessel enlargement. In addition to the well known effects of THs on vasoreactivity, these results suggest that
THs may affect function of small resistance arteries by phenotypic remodeling of vascular smooth muscle cells (VSMC).
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Introduction
THs affect diastolic and systolic function and peripheral
vascular tone [1]. Chronic hypothyroidism can lead to severe left
ventricular dysfunction, chamber dilatation, impaired coronary
blood flow, reduced density of small arterioles, and eventual heart
failure [2]. Many clinical studies also suggest that borderline low
thyroid conditions have a negative prognostic value in cardiac
patients. Not only do heart failure patients have a higher incidence
of low TH function, the HUNT study showed that higher levels of
thyroid stimulating hormone (TSH), which are still within
the normal range, are associated with increased coronary artery
disease mortality in women and unfavorable serum lipids in all
patients [3,4]. The topic of low thyroid function in heart failure
and potential benefits of treatment was reviewed recently by
Gerdes and Iervasi [5].
Animal studies demonstrated beneficial effects of THs on
cardiac remodeling and function in dilated cardiomyopathy,
hypertension, and myocardial infarction without increasing heart
rate above normal values [6,7,8,9]. Of particular relevance to the
current study, we demonstrated impaired resting and maximum
blood flow in BIO-TO2 hamsters, subclinical hypothyroidism, and
normalization of blood flow after TH treatment, which led to
dramatic benefits on underlying cardiac pathology [6]. Cumula-
tively, the above reports suggest that more information is needed
regarding TH regulation of small resistance vessels in the heart
since they may play an important role in coronary blood flow in
heart diseases, particularly in borderline low TH conditions.
The current study examines rapid coronary vascular remodel-
ing in hypothyroid rats after treatment with T3. While the
vasomotor effects of THs have long been recognized, results from
the current study suggest that THs may work through another
previously unrecognized vascular remodeling mechanism to alter
coronary blood flow. This TH-dependent mechanism may be
particularly relevant in borderline low TH conditions, which are
common in heart failure.
Materials and Methods
Animal model and study design
The use of animals in this study conformed to the Public Health
Service Guide for Care and Use of Laboratory Animals.
Experiments were reviewed and approved by the Sanford
Research/University of South Dakota Institutional Animal Care
and Use Committee (Approval ID 08-11-08-11C). Surgical
services were provided by Charles River Laboratories (Wilming-
ton, MA). Female Sprague-Dawley rats had TX at the age of 10
weeks. TX rats were aged a minimum of 8 weeks to establish
hypothyroidism then randomly divided into three experimental
groups (12 rats/group). To ensure adequate TX surgery and
establishment of hypothyroidism, rats with normal heart rate,
body temperature, and TSH levels were excluded from the study.
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24 hours) for 36 h and 72 h, respectively. The other group was
treated with sterile saline as placebo. Twelve age- and sex-matched
Sprague-Dawley rats without surgery served as controls. All
animals were exposed to a 12-hour light-dark cycle and given
standard rat chow and water ad libitum. Serum concentration of
TSH were determined using a TSH ELISA kit (Calbiotech, Spring
Valley, CA). Serum T3 and Thyroxine (T4) were measured
using Total T3 and Total T4 ELISA kits, respectively (Alpha
Diagnostics, San Antonio, TX). Body weight, heart weight, and
heart rate (via echocardiogram) were recorded during terminal
experiments. After echocardiograms were collected, each animal
was deeply anesthetized with 5% isofluorane and the chest cavity
opened. Hearts were arrested in diastole and vasorelaxation was
achieved by injecting freshly prepared 0.2% 2,3-butanedione
monoxime and 0.1% adenosine solution into the left ventricle
(LV). Hearts were then quickly removed, rinsed in ice-cold
phosphate buffered saline (PBS), blotted and weighed. LVs were
dissected and weighed. Apical and basal slices of LVs were stored
frozen for RNA and protein analysis. The remaining tissue was
sliced transversely, embedded in OCT compound (Sakura Finetek
Inc, Torrance, CA) and frozen, or immersion fixed in 10%
formalin for morphometric analysis.
Morphometry
All fluorescence images were acquired using an Olympus
FluoView 1000 confocal laser scanning microscope (Olympus
Corp., Tokyo, Japan). Changes in myocardial arteriolar density
were quantified morphometrically as reported previously [10]. In
addition, we modified the original protocol to enhance recognition
of the smallest arterioles. Combined Isolectin B4 (IB4, marker
of endothelial cells, ECs) and a smooth muscle actin (a-
SMA, immunohistochemical marker of VSMC) were used instead
of a-SMA only. This enabled consistent identification of the
smallest arterioles, which often had incomplete smooth muscle cell
coverage. 3D reconstruction of these small vessels clearly identified
them as arteriolar in nature. In previous studies, these vessels were
not counted. De-paraffinized, re-hydrated tissue sections were
heated to 95uC in 10 mM Na Citrate, pH 5.0 containing 0.05%
Tween-20 for 20 minutes, cooled to room temperature, and
incubated with blocking solution for 30 minutes. Blocking and
antibody diluent solution consisted of 2% Bovine serum albumin
in Tris-buffered saline containing 0.05% Tween-20 and 1 mM
CaCl2. Sections were stained with fluorescein isothiocyanate-
conjugated IB4 (IB4-FITC; Vector Labs, Burlingame, CA;
final dilution 1:200) and a-SMA antibody labeled with Cy3
fluorescent dye (a-SMA-Cy3; Sigma, St. Louis, MO; final
dilution 1:5000) for one hour, rinsed in antibody diluent solution
and coverslipped with Fluoromount G (EMS, Hatfield, PA).
Myocardial arterioles were visualized by confocal microscopy at
206 magnification (35 random fields/heart). Arteriolar length
density (LD, average length of arterioles/unit myocyte volume
[11]) was calculated based on the following formula: LD (mm/
mm
3)=g (a/b)/M, where a and b are the maximum and
minimum external arteriolar diameters, respectively, and M is the
tissue area. Arteriolar LD was converted to total arteriolar length
by multiplying LD (mm/mm
3) by LV weight expressed in mm
3
(,1 mg of cardiac tissue is equivalent to 1 mm
3).
Capillary density was determined by confocal microscopy of
methanol fixed cryosections of OCT embedded LV tissue from
areas containing only circular, cross-sectioned capillary profiles
stained with IB4-FITC and a-SMA-Cy3 (mean sampling area
,0.4 mm
2/per heart). The number of IB4 positive (and a-SMA
negative) capillaries was normalized to tissue area and converted
to total capillary length by multiplying numerical capillary density
(number/mm
2) by LV weight expressed in mm
3.
Ki67-specific antibody (Abcam, Cambridge, MA, final dilution
1:100) and 49,6-diamidino-2-phenylindole (DAPI, Molecular
Probes, Eugene, OR) were used to detect proliferating nuclei in
5 mm cryosections. Secondary antibodies conjugated to Alexa-
Flour-488 or AlexaFlour-568 (Molecular Probes, Eugene, OR)
were diluted 1:1000. IB4-FITC was used to detect ECs. VSMCs
were detected with a-SMA-Cy3. Pericytes were detected with
antibody specific to NG2 or PDGFR-b (gift from Dr. William
Stallcup, Sanford-Burnham Institute for Medical Research, La
Jolla, CA). Co-localization of labeling was determined using
confocal microscopy. 100 microscopic fields per sample (406)
were examined.
Echocardiography
Heart rate was determined echocardiographically using a
VisualSonics Vevo 660 high-resolution imaging system with a
25-MHz RMV-710 transducer (Toronto, ON, Canada) as
reported by our group previously [10]. Animals were lightly
anesthetized with 1.5% isofluorane and M-mode images were
obtained from the short axis of the LV at the level of the papillary
muscles.
Quantitative PCR array
RNA was isolated from 50–100 mg of cardiac tissues using
TRIzol reagent followed by RNA purification with the PureLink
RNA Mini kit and DNA digestion using the PureLink DNase kit
(Invitrogen, Carlsbad, CA). Equal amounts of high quality RNA
from each sample within a particular experimental group were
pooled. cDNA was synthesized using RT
2 First Strand kit
(SABiosciences, Frederick, MD). Expression of 84 angiogenesis
inhibitors and agonists was analyzed by quantitative PCR using
the RT
2 Profiler qPCR Array (cat# PARN-072; SABiosciences,
Frederick, MD) per manufacturer’s instructions. ABI 7500 real-
time PCR instrument operated by Software Version 1.3.0 was
used for all experiments (Life Technologies, Carlsbad, California).
Expression data were analyzed using SABiosciences expression
analysis template in Excel (Microsoft Office 2008).
Statistical analyses
All values are presented as means 6 SEM. One-way ANOVA
models were used for all responses. Post hoc Dunnett’s test was
used to compare all treatment groups with the control group and
with TX group. Statistical analyses were performed using
SigmaStat version 3.5 (Aspire Software International, Ashburn,
VA) and significance was accepted at p,0.05. Linear regression
analysis was performed using SigmaStat version 3.5.
Results
Physical data
Rats with established hypothyroidism (eight weeks after TX)
received intraperitoneal injections of T3 (14 mg/kg) every
24 hours. One group of TX rats was treated for 36 hours (they
received a total of two injections) and another group was treated
for 72 hours (this group received three injections.). The dose,
14 mg/kg/day, was selected to produce a pronounced pharmaco-
logical effect of T3 on the heart. T3 treatment resulted in elevated
levels of circulating T3 (Figure 1A). Heart rate was lower in TX
rats compared to control rats and was normalized to control levels
after 36 hours of T3 treatment. 72 hours of T3 treatment
increased heart rate above the control levels (Figure 1B). Serum
TSH was higher in TX rats when compared to control and was
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(Figure 1C). Circulating T4 concentration in TX animals was
abnormally low and was not affected by T3 treatment (Figure 1D).
TX rats showed significant reduction of body weight, heart weight,
and displayed cardiac atrophy (reduced heart weight to body
weight ratio, HW/BW) compared to controls (Figure 1E–G).
T3 treatment for 72 hours restored HW/BW ratio to control
levels (Figure 1G).
Myocardial capillaries
An increase in capillary density in TX animals (which displayed
significant cardiac atrophy) and reduction of capillary density in
Figure 1. Experimental model and response to treatment. A–G. Changes in serum T3 (A), heart rate (B), serum TSH (C), serum T4 (D), body
weight (E), heart weight (F), and heart weight body weight ratio (HW/BW, G). Con, control; TX, thyroidectomized rats; 36 h, TX rats treated with T3
(14 mg/kg/day) for 36 h; 72 h, TX rats treated with T3 for 72 h; bpm, beats per minute. Values are means 6 SEM. * p,0.05 vs. control; # p,0.05 vs.
TX.
doi:10.1371/journal.pone.0025054.g001
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density inversely correlated with LV weight in TX and T3-treated
animals (Figure 2B). This observation suggests a passive change in
intercapillary distance due to cardiomyocyte atrophy (in TX
animals) or growth (in T3 treated animals). Indeed, when total
capillary length per LV was calculated, no changes were observed
between the groups (Figure 2C).
Myocardial arterioles
Changes in arterioles are shown in Figure 3. While arteriolar
LD was reduced by 23% in the 5 to 30 mm size range in TX rats
versus controls, this did not quite reach statistical significance as
reported in our two previous studies of hypothyroid rats [10,12].
Compared to TX rats, LD of the 5 to 30 mm arterioles increased
by 61% at 36 hours and 91% at 72 hours.
Since the rapid T3-induced increase in small arterioles could be
due to vessel splitting (intussusception), extensive examination was
made of vessels in confocal image stacks. No evidence of arteriolar
splitting was ever observed.
It has been shown that newly formed arterioles are reactive with
a-SMA antibody but not with smooth muscle myosin heavy
chain (SM-MHC) antibody [13]. As these arterioles mature, they
start to express SM-MHC [13]. Consequently, potential T3-related
differences in the expression pattern of a-SMA and SM-MHC were
examined in an effort to detect arteriolar sprouting. Larger
arterioles labeled clearly with both markers (Figure 4A). Although
a dramatic reduction in SM-MHC labeling intensity of the smallest
arterioles was observed, there were no group differences.
Extensive confocal observations of tissue sections co-labeled
with IB4 and a-SMA revealed that many of the smallest arterioles
with a discontinuous layer of smooth muscle were being excluded
with the single labeling approach due to uncertain classification.
Consequently, arteriolar length was reassessed using this dual
labeling method. It should be noted that this new approach led to
improvement in objectivity and reproducibility in measuring small
arterioles. Figure 4B demonstrates how easily small arterioles with
a discontinuous or continuous smooth muscle cell layer can be
identified using dual labeling. In TX rats treated with T3 for
72 hours, an increase in small arterioles (10–18 mm diameter) was
observed (Figure 4C). Of particular note, T3 treatment also led to
a reduction in total length of the smallest arterioles (5–9 mm
range), which included arterioles with a discontinuous smooth
muscle layer (Figure 4C).
T3 induction of cell proliferation
Proliferating cells were detected by the presence of Ki67 antigen
in nuclei, a cellular marker for proliferation expressed during all
active phases of the cell cycle (G1, S, G2, and mitosis). There were
no changes in cell proliferation 36 hours after T3 injection
(Figure 5). T3 treatment for 72 hours, however, led to a significant
increase in the number of Ki67-positive EC, VSMCs, and
pericytes. c-Kit labeling was examined to study the possible role
of stem cells in this process. Labeling frequency was extremely low
(5–9 positive cells per transverse slice of LV and septum of rat
heart, data not shown) and there were no differences between
groups indicating that stem cells may not play a role in the early
stage of T3 mediated arteriolar remodeling induced in hypothy-
roid animals.
T3-induced gene expression
To investigate molecular mechanisms involved in T3-dependent
arteriogenesis, a qPCR array approach targeting 84 potential
activators and inhibitors of microvascular growth was used. We
suspected that, regardless of the etiology of hypothyroidism, TH
treatment of hypothyroid animals should elicit similar gene
expression changes. To test our hypothesis we used two different
models of hypothyroidism: a thyroidectomy model (TX) and
propylthiouracil (PTU) induced model of hypothyroidism
(0.025% PTU was delivered in drinking water over the course of
six weeks; archived frozen LV tissue samples were used to
comprise PTU experimental groups). Variation of expression of
qPCR Array genes was examined across experimental groups
representing different levels of TH function: euthyroid control
(n=3), hypothyroid (TX or PTU; n=4) and reconstituted
hypothyroid (TX+T3 or PTU+T3, n=4). Each sample within
an experimental group consisted of a pool of RNA (4–5 animals
per RNA sample). Expression was normalized to the expression of
housekeeping genes, Rplp1 and Ldha, which deviated minimally
across all experimental groups.
Hypothyroidism significantly affected the expression of five
genes: expression of Angiopoietin 1 (Angpt1) was downregu-
lated and the expression or the remaining four genes was
upregulated (p,0.05, Table 1). Notably, expression pattern of
four out of five genes affected by hypothyroidism (Angpt1, CD55,
Cited1, and Mdk) was reversed by T3 treatment of hypothyroid
animals, (p,0.05, Table 1). Remarkably, T3 treatment upregu-
lated expression of Angpt1 and downregulated expression of
Figure 2. Capillaries are preserved in the hearts of hypothyroid rats. A. Capillary density; B. Linear regression analysis of the correlation
between capillary density and LV weight of the control and TX groups combined; C. LV capillary length. Values are means 6 SEM. * p,0.05 vs.
control; # p,0.05 vs. TX.
doi:10.1371/journal.pone.0025054.g002
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doi:10.1371/journal.pone.0025054.g003
Figure 4. Induction of muscularization of small arterioles by T3 treatment of TX rats. A. Confocal stack projection images of representative
arteriolar branch point in thick (30 mm) cryosections; B. Modified morphometric protocol increases the sensitivity of measurement of small arterioles
with incomplete VSMC coverage; examples of smaller (top panels) and larger vessels (bottom panels); C. Changes of arteriolar size distribution 72 h
after initiation of T3 treatment as compared to arteriolar size distribution in TX rats; a-SMA – alpha smooth muscle actin, IB4 – isolectin B4, SM-MHC –
smooth muscle myosin heavy chain. Values are means 6 SEM.
doi:10.1371/journal.pone.0025054.g004
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was interesting because these two molecules might serve as mutual
antagonists in cardiac angiogenesis. Overall, the qPCR array
experiment identified the Angiopoietin signaling system as one of
the likely targets of TH in the heart.
Discussion
This study investigated early cellular changes triggered by TH
in the coronary microvasculature of hypothyroid rats. Thyroid
hormones and their analogues are known to be pro-angiogenic in
adult heart and can stimulate arteriolar growth in normal heart as
well as after myocardial infarction [14,15,16,17,18]. Previous
studies in our lab have shown that hypothyroidism induced by
PTU treatment led to impaired myocardial blood flow and a
significant reduction in myocardial arterioles [2] as early as three
weeks after initiating the PTU treatment [19]. These changes have
also been confirmed after inducing hypothyroidism by thyroidec-
tomy (TX) in rats. In the TX model of hypothyroidism,
microvascular impairment was prevented by thyroxine (T4) [10]
Figure 5. T3 induces proliferation of microvascular cells in the left ventricle. A–C. Quantitation of Ki67-positive EC (A), pericytes (B), and
VSMC (C); D. Representative images of Ki67-positive nuclei of EC (a–d; IB4
+), pericytes (e–h; PDGFR-b
+) and VSMC (i–l; a-SMA
+) in the left ventricle
(1006). Values are means 6 SEM; * p,0.05 vs. control, # p,0.05 vs. TX.
doi:10.1371/journal.pone.0025054.g005
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demonstrated that arteriolar length in the TX model was restored
within 72 hours after initiation of T3 treatment. To determine the
cellular mechanism responsible for restoration of the microvascu-
lature in the heart, early morphological and cellular events were
investigated.
Animal model and treatment dosage selection
We and others have shown previously that T3 treatment
induces arteriolar growth in the heart. The mechanism of T3
action on arterioles, however, was not clear. To investigate the
mechanism of T3 action on arterioles, we choose an experimental
system which can maximize the growth response. We compared
animals across three different phenotypes: normal, hypothyroid,
and hypothyroid animals treated with T3. The goal of the study
was to detect changes consistent with the thyroid state across
different levels of thyroid function. The model of hypothyroidism
was effective because, despite the apparent lack of suppression of
circulating T3, thyroidectomized animals had elevated TSH
levels, reduced heart rate, and reduced HW/BW ratio, clear signs
of hypothyroidism (Figure 1). The levels of circulating T3 in both
control and TX groups were at the lower end of the detection
limit. The method of T3 detection used in this study (human total
T3 ELISA kit) is optimized for the detection of hyperthyroidism,
with less sensitivity at the lower end where circulating T3 in TX
and control rats were primarily grouped. We chose to treat
hypothyroid animals with 14 mg/kg/day T3 because previous
work from Morreale de Escobar’s laboratory [20] and from our
studies [10] indicated that circulating levels of T3 may not
accurately reflect cardiac tissue level of T3 upon hormone
replacement. Moreover, our ongoing studies indicate that the T3
dose necessary to restore cardiac function is at least three times
higher (,10 mg/kg/day, over the course of two weeks) than the
T3 dose necessary to restore circulating levels of T3 (AM Gerdes
and NY Weltman, unpublished observations). Thus, we selected a
pharmacological dose leading to a slight elevation of heart rate to
ensure a strong T3-angiogenic stimulus without inducing marked
hyperthyroidism. We also chose to examine animals at early time
periods (36 and 72 hours) since little is known about the early
changes elicited by T3 on coronary vasculature both at the
molecular and at the anatomical levels during this period.
Arteriolar atrophy in hypothyroid rat heart
Arteriolar length density (mm/mm‘3) was not significantly
different between control and TX rats in this study. When
corrected to the reduced LV weight, however, total arteriolar
length in hypothyroid rats was significantly reduced in TX rats
compared to control rats (data not shown). Based on our
cumulative results, we interpreted this reduction as arteriolar
atrophy. The mechanisms that trigger coronary arteriolar atrophy
in hypothyroidism are likely to be the same as those that cause left
ventricular atrophy: decreased rate of metabolism and reduced
blood flow. Of note, total capillary length in LV was not affected
by thyroidectomy or T3 treatment (Figure 2). It appears that
intercapillary distance in the vascular bed of the heart passively
changes depending on TH-induced changes in myocyte cross-
sectional area.
T3 does not induce sprouting and splitting of coronary
arterioles in TX rats
The observation that T3 induced significant arteriolar growth
within only three days was remarkable (Figure 3). Could sprouting
angiogenesis account for such a rapid increase in arterioles? To
evaluate this possible mechanism, we performed extensive
histological examination of cryosections in search of spatial
patterns of cell proliferation suggestive of sprouting. Sprouts in
whole tissue should be characterized by the presence of
proliferating nuclei aligned in a linear direction with the vessel.
After examining of hundreds of sections from T3 treated animals,
we were unable to observe any examples of arteriolar or capillary
Table 1. Thyroid hormone-dependent cardiac mRNA transcripts.
Gene Symbol Gene Name Fold Regulation p-value
Genes Over-Expressed in Hypothyroid vs. Control Rats
Cd55 CD55 molecule, decay accelerating factor for complement 2.5 0.001
Cited1 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 1.9 0.035
Cxcl10 chemokine (C-X-C motif) ligand 10 2.6 0.027
Mdk midkine 7 0.01
Genes Under-Expressed in Hypothyroid vs. Control Rats
Angpt1 angiopoietin 1 22.3 0.047
Genes Over-Expressed in T3-treated vs. Untreated Hypothyroid Rats
Angpt1 angiopoietin 1 2.6 0.021
Genes Under-Expressed in T3-treated vs. Untreated Hypothyroid Rats
Angpt2 angiopoietin 2 21.7 0.046
Angptl3 angiopoietin-like 3 24.2 0.044
Cd55 CD55 molecule, decay accelerating factor for complement 22 0.005
Cited1 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 24.8 0.001
Erbb2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 23.1 0.027
Foxo4 forkhead box O4 22.3 0.024
Mdk midkine 27.1 0.003
Smo smoothened homolog (Drosophila) 22.4 0.031
doi:10.1371/journal.pone.0025054.t001
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36 hours of T3 treatment and only single proliferating ECs,
pericytes, and VSMCs were observed interspersed within the
tissue after 72 hours of treatment (Figure 5). Additionally, the
labeling pattern for a-SMA and SM-MHC was similar in all
animal groups with reduced SM-MHC labeling being a common
feature of the smallest arterioles (Figure 4A). If sprouting
angiogenesis of small arterioles had occurred, a T3-mediated
increase in the number or length of SM-MHC positive small
arterioles would have been anticipated as reported previously in
young growing animals [13].
The presence of Ki67 positive cells at the 72 hour timepoint
likely marks the beginning of capillary proliferation, which has
been noted at later timepoints by others [21]. Regarding the rapid
T3-mediated increase in arteriolar density, it is safe to conclude
that sprouting angiogenesis did not play a role in the time frame
examined.
The potential role of intussusception (vessel splitting) was
examined next. Intussusception can occur very quickly with
minimal cell proliferation and has been observed in fetal and early
postnatal heart [22]. After extensive examination of IB4/a-SMA
labeled arterioles by confocal microscopy, we were unable to find a
single example of intussusception. Thus, morphogenesis of
coronary arterioles by splitting is unlikely to play a role in the
model and time frame examined.
T3 induces muscularization of VSMC
When quantitating arterioles with an a-SMA label only, many
small individual positive cells were noted. These cells were
routinely ignored in arteriolar quantitation in previous studies
because they are not associated with a continuous vascular smooth
muscle cell layer. Spatial examination of vessels after dual labeling
with IB4 (EC marker) and a-SMA (VSMC marker) revealed that
these a-SMA positive cells represented a subset of smaller
arterioles with discontinuous a-SMA labeling (Figure 4B). This
arteriolar subset (5–9 mm diameter) was decreased in T3-treated
animals compared to untreated hypothyroid rats (Figure 4C).
Thus, it appears that T3 promotes a more differentiated
phenotype of VSMCs characterized by re-expression of a-SMA.
VSMCs are known to have a high capacity for phenotypic
‘‘switching’’. Phenotypic switching involves loss of expression of a-
SMA and other markers of differentiated VSMCs and re-
expression of factors that suppress VSMC differentiation,
including Kru ¨ppel-like zinc finger 4 (Klf4), HERP, and Elk [23].
Thyroid function correlates with the expression of
angiopoietins 1 and 2 in rat heart
It has been demonstrated that TH binds to surface receptors on
ECs and activates intracellular signaling pathways promoting
sprouting angiogenesis [24,25]. Less is known about the action of
TH on VSMCs. To identify molecular factors that can play a role
in T3-induced coronary remodeling, we used a commercially
available qPCR array targeting expression of 84 inducers and
inhibitors of angiogenesis (Table 1). We looked for significant
changes in gene expression induced by hypothyroidism and
restored by T3 treatment in adult rat heart. We observed that
expression of Angpt1 in heart positively correlated with TH
function. Conversely, the expression of Angpt2 (a negative
regulator of Angpt1 [26]) was decreased by T3 treatment. In
neonatal development, Angpt1 acts to enlarge blood vessels by
recruiting periendothelial support cells without inducing sprouting
[27,28,29]. In adult organisms, Angpt1 gene transfer could
modulate collateral vessel development (as has been shown in a
rabbit model of hind limb ischemia) [30]. It appears that TH could
regulate the angiopoietin system in adult heart. Further studies are
needed to delineate the mechanisms of action of angiopoietins in
coronary remodeling.
Angpt1 was previous characterized as a pro-angiogenic target of
the TH analogue DITPA [16]. The genomic sequence upstream
of angpt1 gene in rat and human, indeed, contains two conserved
TH response elements. It would be interesting to examine in a
future study if TH receptor directly binds to the promoter of
Angpt1 in VSMSs and whether ligation of TH receptor influences
the levels of Angp1 gene expression.
Chronic bradycardia was shown to have a beneficial effect on
coronary revascularization in rats with myocardial infarction by
upregulation of several growth factors and their receptors, namely,
VEGF, Flt-1, and bFGF. In contrast, the angiopoietin system was
not affected by bradycardia [31]. Thyroid hormones appear to
influence coronary remodeling by different mechanisms, with
expression of Angpt1 and Angpt2 in the heart prominently
affected. It is possible, that despite increasing heart rate, TH
deliver stimuli sufficient to sustain beneficial remodeling of
resistance vessels to improve coronary circulation.
Cumulatively, our observations suggest that thyroid hormones
may play an important role in promoting a more differentiated
phenotype of VSMCs. It appears that the ‘‘missing’’ small
arterioles in hearts from hypothyroid rats observed by our group
previously may actually be present in a dedifferentiated state.
Since we have previously shown that this alteration in small
arterioles is associated with a dramatic reduction in maximum
coronary blood flow in hypothyroid rats [2], T3-induced
modulation of VSMC phenotype may play a major role in the
regulation of blood flow. Increased muscularization of small
arterioles in response to T3 defines an anatomical feature that
might support better regulation of coronary flow reserve. Of note
here, BIO-TO2 hamsters have subclinical hypothyroidism and a
pattern of impaired coronary blood flow similar to that of
hypothyroid rats [6]. Treatment of BIO-TO2 hamsters with
thyroid hormones restored coronary blood flow to normal [6].
Although cardiac patients are typically classified as ischemic or
non-ischemic based on patency of major coronary arteries,
evidence from patients with idiopathic dilated cardiomyopathy
has demonstrated the presence of significant vascular dysfunction
[32,33,34]. When considering the high incidence of low thyroid
function in heart failure patients, it is likely that impaired blood
flow and flow reserve in many of these patients may be related to
the effects of thyroid hormones on small coronary resistance
vessels, as observed here.
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